CL2023002015A1 - Composiciones y métodos para el tratamiento de la enfermedad de fabry. - Google Patents

Composiciones y métodos para el tratamiento de la enfermedad de fabry.

Info

Publication number
CL2023002015A1
CL2023002015A1 CL2023002015A CL2023002015A CL2023002015A1 CL 2023002015 A1 CL2023002015 A1 CL 2023002015A1 CL 2023002015 A CL2023002015 A CL 2023002015A CL 2023002015 A CL2023002015 A CL 2023002015A CL 2023002015 A1 CL2023002015 A1 CL 2023002015A1
Authority
CL
Chile
Prior art keywords
methods
fabry disease
compositions
treatment
polynucleotides
Prior art date
Application number
CL2023002015A
Other languages
English (en)
Inventor
Sean Armour
Daniel Cohen
Christopher Riling
Original Assignee
Spark Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spark Therapeutics Inc filed Critical Spark Therapeutics Inc
Publication of CL2023002015A1 publication Critical patent/CL2023002015A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen polinucleótidos que incluyen ácidos nucleicos que codifican α-galactosidasa A (GLA). También se describen casetes de expresión, vectores, células y líneas celulares que contienen los polinucleótidos, y también métodos para usar los polinucleótidos para tratar trastornos de almacenamiento lisosómico tal como la enfermedad de Fabry.
CL2023002015A 2021-01-14 2023-07-11 Composiciones y métodos para el tratamiento de la enfermedad de fabry. CL2023002015A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163137235P 2021-01-14 2021-01-14
US202163264356P 2021-11-19 2021-11-19

Publications (1)

Publication Number Publication Date
CL2023002015A1 true CL2023002015A1 (es) 2024-03-08

Family

ID=82448637

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002015A CL2023002015A1 (es) 2021-01-14 2023-07-11 Composiciones y métodos para el tratamiento de la enfermedad de fabry.

Country Status (12)

Country Link
US (1) US20240301380A1 (es)
EP (1) EP4277988A1 (es)
JP (1) JP2024504611A (es)
KR (1) KR20230131246A (es)
AU (1) AU2022207185A1 (es)
CA (1) CA3208153A1 (es)
CL (1) CL2023002015A1 (es)
CO (1) CO2023010599A2 (es)
IL (1) IL304273A (es)
MX (1) MX2023008362A (es)
PE (1) PE20240915A1 (es)
WO (1) WO2022155665A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4426846A1 (en) * 2021-11-03 2024-09-11 Sangamo Therapeutics, Inc. Methods for use of viral vector constructs for the treatment of fabry disease
CN117551636A (zh) * 2023-04-30 2024-02-13 四川至善唯新生物科技有限公司 工程化α-GAL A肽及其功能变体和治疗法布里病的相关方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2833923A4 (en) * 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
JP7114485B2 (ja) * 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド

Also Published As

Publication number Publication date
AU2022207185A9 (en) 2024-07-25
JP2024504611A (ja) 2024-02-01
IL304273A (en) 2023-09-01
CA3208153A1 (en) 2022-07-21
PE20240915A1 (es) 2024-04-30
WO2022155665A1 (en) 2022-07-21
AU2022207185A1 (en) 2023-07-13
US20240301380A1 (en) 2024-09-12
CO2023010599A2 (es) 2023-09-18
EP4277988A1 (en) 2023-11-22
KR20230131246A (ko) 2023-09-12
MX2023008362A (es) 2023-10-04

Similar Documents

Publication Publication Date Title
CL2023002015A1 (es) Composiciones y métodos para el tratamiento de la enfermedad de fabry.
BR112022002581A2 (pt) Inibidores heterocíclicos de rip1 quinase
PE20180675A1 (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos
BR112018003031A2 (pt) formulações clínicas
ECSP17028310A (es) Composiciones y métodos para inhibir la expresión del gen HAO1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))
UY38160A (es) Partículas implantables y métodos relacionados
ECSP066672A (es) Métodos para tratar asma
AR069168A1 (es) Variantes de alfa -amilasas con propiedades alteradas
ES2530995T3 (es) Supresión de tumor usando perfusato placentario humano y células asesinas naturales intermediarias que provienen de placenta humana
UY36416A (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de la mieloperoxidasa
AR094755A1 (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
BRPI0408735A (pt) polinucleotìdeo isolado, construção de ácido nucléico, célula transgênica, organismo transgênico, vegetal transgênico, método para produzir um vegetal transgênico, método para expressar um polinucleotìdeo de interesse em uma célula, e método para co-expressar dois polinucleotìdeos de interesse em uma célula
AR074124A1 (es) Composiciones y metodos para inhibir la expresion de genes del factor vii
MX2021000328A (es) Enzimas de variantes de galactosa oxidasa modificadas geneticamente.
MX2021000322A (es) Enzimas de variante fosfopentomutasa modificada geneticamente.
AR042442A1 (es) Casete de expresion que codifica una hidroxi - fenil- piruvato - dioxigenasa y plantas que contienen tal gen, que son tolerantes a los herbicidas
CR9395A (es) Compuestos utiles para inhibir chk1
MX2021000327A (es) Enzimas de variante de fosforilasa de nucleosido de purina modificadas geneticamente.
AR111192A1 (es) Métodos para aumentar el rendimiento del grano
EA202091205A1 (ru) Композиции для терапии гипергликемии и сопутствующих состояний
EA201990034A1 (ru) Ферментативное гликозилирование стевиолгликозидов и других соединений с глюкозо-1-фосфатом
CL2022001503A1 (es) Agentes de arni del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72), composiciones
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
MX2023008801A (es) Composiciones y metodos para tratar angioedema hereditario.
MX2021000323A (es) Enzimas de variante de pantotenato quinasa modificadas geneticamente.